Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The BCL2L11 (BIM) deletion polymorphism is a possible criterion for discontinuation of imatinib in chronic myeloid leukaemia patients.

× No keyword cloud information.

7 in total

1. A multicenter clinical study evaluating the confirmed complete molecular response rate in imatinib-treated patients with chronic phase chronic myeloid leukemia by using the international scale of real-time quantitative polymerase chain reaction.

Authors: Yoshinori Shinohara; Naoto Takahashi; Kaichi Nishiwaki; Masayuki Hino; Makoto Kashimura; Hisashi Wakita; Yoshiaki Hatano; Akira Hirasawa; Yasuaki Nakagawa; Kuniaki Itoh; Hidekazu Masuoka; Nobuyuki Aotsuka; Yasuhiro Matsuura; Sinobu Takahara; Koji Sano; Jun Kuroki; Tomoko Hata; Hirohisa Nakamae; Atsuko Mugitani; Takahiko Nakane; Yasushi Miyazaki; Takenori Niioka; Masatomo Miura; Kenichi Sawada
Journal: Haematologica Date: 2013-05-28 Impact factor: 9.941

Review 2. The BCL2 Family: Key Mediators of the Apoptotic Response to Targeted Anticancer Therapeutics.

Authors: Aaron N Hata; Jeffrey A Engelman; Anthony C Faber
Journal: Cancer Discov Date: 2015-04-20 Impact factor: 39.397

3. The effect of BIM deletion polymorphism on intrinsic resistance and clinical outcome of cancer patient with kinase inhibitor therapy.

Authors: Hou-Qun Ying; Jie Chen; Bang-Shun He; Yu-Qin Pan; Feng Wang; Qi-Wen Deng; Hui-Ling Sun; Xian Liu; Shu-Kui Wang
Journal: Sci Rep Date: 2015-06-15 Impact factor: 4.379

4. Downregulated microRNA-148b in circulating PBMCs in chronic myeloid leukemia patients with undetectable minimal residual disease: a possible biomarker to discontinue imatinib safely.

Authors: Junko H Ohyashiki; Kazushige Ohtsuki; Izuru Mizoguchi; Takayuki Yoshimoto; Seiichiro Katagiri; Tomohiro Umezu; Kazuma Ohyashiki
Journal: Drug Des Devel Ther Date: 2014-08-25 Impact factor: 4.162

5. The BCL2L11 deletion polymorphism is not associated with imatinib resistance in chronic myeloid leukemia patients: meta-analysis.

Authors: Jinyun Xu; Jiaowei Gu; Yan Zhao; Huihua Meng; Li'an Du; Ruibo Zhang; Hao Jiang; Jianming Luo
Journal: Oncotarget Date: 2017-09-22

6. Monocytic myeloid-derived suppressor cells as prognostic factor in chronic myeloid leukaemia patients treated with dasatinib.

Authors: Cesarina Giallongo; Nunziatina L Parrinello; Piera La Cava; Giuseppina Camiolo; Alessandra Romano; Marina Scalia; Fabio Stagno; Giuseppe A Palumbo; Roberto Avola; Giovanni Li Volti; Daniele Tibullo; Francesco Di Raimondo
Journal: J Cell Mol Med Date: 2017-12-08 Impact factor: 5.310

7. [Relationship between BIM gene polymorphism and therapeutic efficacy in the retreatment of advanced non-small cell lung cancer with tyrosine kinase inhibitor].

Authors: Lei Zheng; Baochai Lin; Zhengbo Song; Fangjun Xie; Wei Hong; Jianguo Feng; Lan Shao; Yingping Zhang
Journal: Zhongguo Fei Ai Za Zhi Date: 2013-12

7 in total